Li Watsek
Stock Analyst at Cantor Fitzgerald
(2.43)
# 2,511
Out of 5,105 analysts
77
Total ratings
52.5%
Success rate
-2.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Li Watsek
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPX Compass Therapeutics | Initiates: Overweight | n/a | $5.16 | - | 1 | Dec 3, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $203 → $254 | $220.42 | +15.23% | 20 | Oct 13, 2025 | |
| CNTX Context Therapeutics | Initiates: Overweight | n/a | $1.04 | - | 1 | Oct 2, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | n/a | $34.03 | - | 3 | Sep 9, 2025 | |
| REPL Replimune Group | Upgrades: Overweight | n/a | $10.18 | - | 2 | Jul 30, 2025 | |
| KURA Kura Oncology | Reiterates: Overweight | n/a | $10.22 | - | 11 | Jun 26, 2025 | |
| ZLAB Zai Lab | Reiterates: Overweight | n/a | $17.77 | - | 1 | Mar 27, 2025 | |
| ACRV Acrivon Therapeutics | Reiterates: Overweight | n/a | $2.53 | - | 2 | Mar 26, 2025 | |
| TARA Protara Therapeutics | Initiates: Overweight | n/a | $5.70 | - | 1 | Mar 14, 2025 | |
| ARVN Arvinas | Reiterates: Overweight | n/a | $12.58 | - | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.47 | - | 7 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $21.53 | - | 4 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.45 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.16 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.37 | - | 5 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $2.03 | +47.78% | 4 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.15 | +334.78% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $38 | $1.89 | +1,910.58% | 1 | Aug 12, 2022 |
Compass Therapeutics
Dec 3, 2025
Initiates: Overweight
Price Target: n/a
Current: $5.16
Upside: -
Ascendis Pharma
Oct 13, 2025
Maintains: Overweight
Price Target: $203 → $254
Current: $220.42
Upside: +15.23%
Context Therapeutics
Oct 2, 2025
Initiates: Overweight
Price Target: n/a
Current: $1.04
Upside: -
IDEAYA Biosciences
Sep 9, 2025
Reiterates: Overweight
Price Target: n/a
Current: $34.03
Upside: -
Replimune Group
Jul 30, 2025
Upgrades: Overweight
Price Target: n/a
Current: $10.18
Upside: -
Kura Oncology
Jun 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $10.22
Upside: -
Zai Lab
Mar 27, 2025
Reiterates: Overweight
Price Target: n/a
Current: $17.77
Upside: -
Acrivon Therapeutics
Mar 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $2.53
Upside: -
Protara Therapeutics
Mar 14, 2025
Initiates: Overweight
Price Target: n/a
Current: $5.70
Upside: -
Arvinas
Feb 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $12.58
Upside: -
Jan 24, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.47
Upside: -
Oct 7, 2024
Reiterates: Overweight
Price Target: n/a
Current: $21.53
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.45
Upside: -
May 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.16
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.37
Upside: -
Nov 22, 2023
Reiterates: Overweight
Price Target: $3
Current: $2.03
Upside: +47.78%
Sep 7, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.15
Upside: +334.78%
Aug 12, 2022
Maintains: Overweight
Price Target: $60 → $38
Current: $1.89
Upside: +1,910.58%